Research Analysts’ Recent Ratings Updates for Amylyx Pharmaceuticals (AMLX)

Several analysts have recently updated their ratings and price targets for Amylyx Pharmaceuticals (NASDAQ: AMLX):

• 11/10/2026 – Amylyx Pharmaceuticals had its price target raised by Mizuho from $38.00 to $39.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Amylyx Pharmaceuticals was given a new $45.00 price target by Stifel Nicolaus.
• 11/5/2026 – Amylyx Pharmaceuticals is now covered by HC Wainwright. They set a “strong-buy” rating on the stock.
• 11/3/2026 – Amylyx Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Amylyx Pharmaceuticals had its price target raised by Citigroup from $32.00 to $39.00. They now have a “buy” rating on the stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $31.80 on Thursday. The firm has a 50-day moving average of $29.81 and a 200-day moving average of $20.63. Amylyx Pharmaceuticals, Inc. has a one year low of $10.83 and a one year high of $41.14. The company has a market cap of $4.09 billion, a PE ratio of -22.08 and a beta of -0.09.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, hitting the consensus estimate of ($0.38). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 10,810 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the transaction, the chief financial officer owned 233,625 shares of the company’s stock, valued at $7,560,105. The trade was a 4.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George M. Milne, Jr. sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the completion of the sale, the director owned 782,881 shares in the company, valued at $21,685,803.70. This represents a 3.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 60,374 shares of company stock worth $1,815,257. Company insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.